The FDA may begin using blockchain systems to help drug and medical products reviews and recalls, according to CoinDesk.
Amy Abernethy, MD, the FDA principal deputy commissioner, said the administration is seeking to modernize the way healthcare providers, drug manufacturers and regulatory agencies communicate. She made the announcement Aug. 22 at the Office of the National Coordinator for Health IT Third Interoperability Forum.
Although details were sparse, Dr. Abernethy said the FDA plans to roll out artificial intelligence, application programing interfaces and blockchain.
"I want FDA to get our own technical house in order so that tech can 'snap in' — we can be agile and efficient. We need to be able to have common interfaces with industry so we can pass data between our organizations, have collaborative review, etc.," Dr. Abernethy said.